Bmi‐1 Overexpression Improves Sarcopenia Induced by 1,25(OH)₂D₃ Deficiency and Downregulates GATA4‐Dependent Rela Transcription

Abstract

Sarcopenia increases with age, and an underlying mechanism needs to be determined to help with designing more effective treatments. This study aimed to determine whether 1,25(OH)2D3 deficiency could cause cellular senescence and a senescence‐associated secretory phenotype (SASP) in skeletal muscle cells to induce sarcopenia, whether GATA4 could be upregulated by 1,25(OH)2D3 deficiency to promote SASP, and whether Bmi‐1 reduces the expression of GATA4 and GATA4‐dependent SASP induced by 1,25(OH)2D3 deficiency in skeletal muscle cells. Bioinformatics analyses with RNA sequencing data in skeletal muscle from physiologically aged and young mice were conducted. Skeletal muscles from 2‐month‐old young and 2‐year‐old physiologically aged wild‐type (WT) mice and 8‐week‐old WT, Bmi‐1 mesenchymal transgene (Bmi‐1Tg), Cyp27b1 homozygous (Cyp27b1−/−), and Bmi‐1TgCyp27b1−/− mice were observed for grip strength, cell senescence, DNA damage, and NF‐κB‐mediated SASP signaling of skeletal muscle. We found that muscle‐derived Bmi‐1 and vitamin D receptor (VDR) decreased with physiological aging, and DNA damage and GATA4‐dependent SASP activation led to sarcopenia. Furthermore, 1,25(OH)2D3 deficiency promoted DNA damage‐induced GATA4 accumulation in muscles. GATA4 upregulated Rela at the region from −1448 to −1412 bp at the transcriptional level to cause NF‐κB‐dependent SASP for aggravating cell senescence and muscular dysfunction and sarcopenia. Bmi‐1 overexpression promoted the ubiquitination and degradation of GATA4 by binding RING1B, which prevented cell senescence, SASP, and dysfunctional muscle, and improved sarcopenia induced by 1,25(OH)2D3 deficiency. Thus, Bmi‐1 overexpression improves sarcopenia induced by 1,25(OH)2D3 deficiency, downregulates GATA4‐dependent Rela transcription, and sequentially inhibits GATA4‐dependent SASP in muscle cells. Therefore, Bmi‐1 overexpression could be used for translational gene therapy for the ubiquitination of GATA4 and prevention of sarcopenia. © 2023 American Society for Bone and Mineral Research (ASBMR).